We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Greater Controls Recommended for Genetic Testing

By LabMedica International staff writers
Posted on 25 Jun 2009
Public and private agencies calling for greater control of genetic testing have given rise to recommendations for new directives.

Evaluation of genomic applications in practice and prevention (EGAPP) is a project initiated by the CDC Office of Public Health Genomics some years ago. The project's goal is to establish and evaluate a systematic, evidence-based process for assessing genetic tests and other applications of genomic technology, in transition from clinical and public health practice to research. EGAPP published an article in the online edition of the journal Genetics in Medicine in January 2009, which described the group's methodology.

Guidelines, published by the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) in 2009, focus on molecular diagnostic companies, and medical and public health professionals who evaluate lab practices and policies.

New York State (USA) has introduced regulations for companies offering direct to consumer genetic testing programs. These have been added to a growing list of public and private agency demands for regulation of genetic testing, laboratory developed tests (LDTs), and in vitro diagnostic multivariate index assays (IVDMIAs).

The new reports belong to a growing list of those focused on bringing genetic testing performance on par with conventional diagnostic tests. Meanwhile, the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH, Bethesda, MD, USA), announced the latest round of grant awards totaling more than US $13.3 million. These awards are aimed at speeding the development of innovative sequencing technologies that reduce the cost of DNA sequencing, and expand the use of genomics in health care and medical research.

"There has been significant progress over the last several years to develop faster and more cost-effective sequencing technologies and, we are committed to supporting these innovative efforts to benefit scientific labs and medical clinics," said NHGRI director Francis S. Collins, M.D., Ph.D.

Related Links:
EGAPP
CDC
NIH



New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Portable Electronic Pipette
Mini 96
Hemodynamic System Monitor
OptoMonitor
Blood Glucose Test Strip
AutoSense Test

Latest Molecular Diagnostics News

Fast Low-Cost Alzheimer’s Tests Could Detect Disease in Early and Silent Stages
25 Jun 2009  |   Molecular Diagnostics

Further Investigation of FISH-Negative Tests for Renal Cell Carcinoma Improves Diagnostic Accuracy
25 Jun 2009  |   Molecular Diagnostics

First Direct Measurement of Dementia-Linked Proteins to Enable Early Alzheimer’s Detection
25 Jun 2009  |   Molecular Diagnostics



GLOBE SCIENTIFIC, LLC